ROCHELLE ELAYDA: Open Payments
NPI 1336649953 · SUMMERVILLE, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,134 in 55 payments from 20 companies in 2025. Trend: 2023 $2,095 · 2024 $1,809 · 2025 $1,134
Food & beverage: $1,134
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 11 | $218 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $112 |
| PFIZER INC. | 6 | $106 |
| Xeris Pharmaceuticals, Inc. | 1 | $92 |
| Novo Nordisk Inc | 5 | $81 |
| Lilly USA, LLC | 4 | $76 |
| Amgen Inc. | 4 | $62 |
| Phathom Pharmaceuticals, Inc. | 3 | $58 |
| Sumitomo Pharma America, Inc. | 2 | $55 |
| GlaxoSmithKline, LLC. | 2 | $38 |
Products named: CAPLYTA, KEVEYIS, AIRSUPRA, FARXIGA, VOQUEZNA, GEMTESA, PREVNAR 20, OTEZLA.
Industry payments across SC — which companies pay providers there.
